- Home
- XXII vs SNPX Comparison
XXII vs SNPX Comparison
Compare XXII & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- SNPX
- Stock Information
- Founded
- XXII 1998
- SNPX 2012
- Country
- XXII United States
- SNPX United States
- Employees
- XXII N/A
- SNPX N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- XXII Health Care
- SNPX Health Care
- Exchange
- XXII Nasdaq
- SNPX Nasdaq
- Market Cap
- XXII 4.0M
- SNPX 4.1M
- IPO Year
- XXII N/A
- SNPX N/A
- Fundamental
- Price
- XXII $0.09
- SNPX $2.40
- Analyst Decision
- XXII
- SNPX Strong Buy
- Analyst Count
- XXII 0
- SNPX 1
- Target Price
- XXII N/A
- SNPX $14.00
- AVG Volume (30 Days)
- XXII 9.6M
- SNPX 18.6K
- Earning Date
- XXII 11-12-2024
- SNPX 11-12-2024
- Dividend Yield
- XXII N/A
- SNPX N/A
- EPS Growth
- XXII N/A
- SNPX N/A
- EPS
- XXII N/A
- SNPX N/A
- Revenue
- XXII $9,918,000.00
- SNPX N/A
- Revenue This Year
- XXII $56.94
- SNPX N/A
- Revenue Next Year
- XXII $2.98
- SNPX N/A
- P/E Ratio
- XXII $0.03
- SNPX N/A
- Revenue Growth
- XXII N/A
- SNPX N/A
- 52 Week Low
- XXII $0.09
- SNPX $2.32
- 52 Week High
- XXII $5.28
- SNPX $8.78
- Technical
- Relative Strength Index (RSI)
- XXII 31.38
- SNPX 33.10
- Support Level
- XXII $0.09
- SNPX $2.88
- Resistance Level
- XXII $0.13
- SNPX $3.20
- Average True Range (ATR)
- XXII 0.01
- SNPX 0.19
- MACD
- XXII 0.01
- SNPX -0.06
- Stochastic Oscillator
- XXII 10.51
- SNPX 8.88
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.